Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In Silico Design and Evaluation of a Novel Therapeutic Agent Against the Spike Protein as a Novel Treatment Strategy for COVID-19 Treatment

Author(s): Soroush Sarmadi, Mohammad Reza Rahbar, Hamideh Najafi, Onyeka S. Chukwudozie and Mohammad Hossein Morowvat*

Volume 18, Issue 2, 2024

Published on: 05 June, 2023

Page: [162 - 176] Pages: 15

DOI: 10.2174/1872208317666230523105759

Price: $65

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that is associated with severe damage to other human organs. It causes by a novel coronavirus, and it is spreading all over the world. To date, there is some approved vaccine or therapeutic agent which could be effective against this disease. But their effectiveness against mutated strains is not studied completely. The spike glycoprotein on the surface of the coronaviruses gives the virus the ability to bind to host cell receptors and enter cells. Inhibition of attachment of these spikes can lead to virus neutralization by inhibiting viral entrance.

Aims: In this study, we tried to use the virus entrance strategy against itself by utilizing virus receptor (ACE-2) in order to design an engineered protein consisting of a human Fc antibody fragment and a part of ACE-2, which reacts with virus RBD, and we also evaluated this interaction by computational methods and in silico methods. Subsequently, we have designed a new protein structure to bind with this site and inhibit the virus from attaching to its cell receptor, mechanically or chemically.

Methods: Various in silico software, bioinformatics, and patent databases were used to retrieve the requested gene and protein sequences. The physicochemical properties and possibility of allergenicity were also examined. Three-dimensional structure prediction and molecular docking were also performed to develop the most suitable therapeutic protein.

Results: The designed protein consisted of a total of 256 amino acids with a molecular weight of 28984.62 and 5.92 as a theoretical isoelectric point. Instability and aliphatic index and grand average of hydropathicity are 49.99, 69.57 and -0.594, respectively.

Conclusions: In silico studies can provide a good opportunity to study viral proteins and new drugs or compounds since they do not need direct exposure to infectious agents or equipped laboratories. The suggested therapeutic agent should be further characterized in vitro and in vivo.

« Previous Next »
Graphical Abstract

[1]
Robson B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Comput Biol Med 2020; 119: 103670.
[http://dx.doi.org/10.1016/j.compbiomed.2020.103670] [PMID: 32209231]
[2]
Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity 2020; 53(2): 248-63.
[http://dx.doi.org/10.1016/j.immuni.2020.07.005] [PMID: 32717182]
[3]
Valitutto MT, Aung O, Tun KYN, et al. Detection of novel coronaviruses in bats in Myanmar. PLoS One 2020; 15(4): e0230802.
[http://dx.doi.org/10.1371/journal.pone.0230802] [PMID: 32271768]
[4]
Lam TTY, Jia N, Zhang YW, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020; 583(7815): 282-5.
[http://dx.doi.org/10.1038/s41586-020-2169-0] [PMID: 32218527]
[5]
Ludwig S, Zarbock A. Coronaviruses and SARS-CoV-2: A brief overview. Anesth Analg 2020; 131(1): 93-6.
[http://dx.doi.org/10.1213/ANE.0000000000004845] [PMID: 32243297]
[6]
Zhang XY, Huang HJ, Zhuang DL, et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty 2020; 9(1): 99.
[http://dx.doi.org/10.1186/s40249-020-00691-6] [PMID: 32690096]
[7]
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020; 80(6): 607-13.
[http://dx.doi.org/10.1016/j.jinf.2020.03.037] [PMID: 32283152]
[8]
Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS‐CoV ‐2 during an outbreak in Iran: Comparison with SARS and MERS. Rev Med Virol 2020; 30(3): e2107.
[http://dx.doi.org/10.1002/rmv.2107] [PMID: 32267987]
[9]
Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J 2020; 43(4): 328-33.
[http://dx.doi.org/10.1016/j.bj.2020.04.007] [PMID: 32387617]
[10]
Anonymous . COVID-19 weekly epidemiological update-12/9/2020. WHO 2020.
[11]
Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol 2021; 21(4): 195-7.
[http://dx.doi.org/10.1038/s41577-021-00526-x] [PMID: 33674759]
[12]
Anonymous . Off-label use of medicines for COVID-19. WHO 2020.
[13]
Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020; 2020.10.15.20209817.
[14]
Shi Y, Wang G, Cai X, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 21(5): 343-60.
[http://dx.doi.org/10.1631/jzus.B2000083] [PMID: 32425000]
[15]
Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020; 581(7807): 221-4.
[http://dx.doi.org/10.1038/s41586-020-2179-y] [PMID: 32225175]
[16]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-292.e6.
[http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
[17]
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260-3.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[18]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367(6485): 1444-8.
[http://dx.doi.org/10.1126/science.abb2762] [PMID: 32132184]
[19]
Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine 2020; 133: 155151.
[http://dx.doi.org/10.1016/j.cyto.2020.155151] [PMID: 32544563]
[20]
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020; 11: 1446.
[http://dx.doi.org/10.3389/fimmu.2020.01446] [PMID: 32612617]
[21]
Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makhawi AM. Cytokine storm in COVID-19 patients, its impact on organs and potential treatment by QTY code-designed detergent-free chemokine receptors. Mediators Inflamm 2020; 2020: 8198963.
[http://dx.doi.org/10.1155/2020/8198963] [PMID: 33029105]
[22]
Linsky TW, Vergara R, Codina N, et al. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science 2020; 370(6521): 1208-14.
[http://dx.doi.org/10.1126/science.abe0075] [PMID: 33154107]
[23]
Cao L, Goreshnik I, Coventry B, et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 2020; 370(6515): 426-31.
[http://dx.doi.org/10.1126/science.abd9909] [PMID: 32907861]
[24]
Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000; 28(1): 235-42.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[25]
HeeShin W. Prediction of protein structure and interaction by GALAXY protein modeling programs. Biodesign 2014; 2: 1-11.
[26]
Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26(2): 283-91.
[http://dx.doi.org/10.1107/S0021889892009944]
[27]
Colovos C, Yeates TO. Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Sci 1993; 2(9): 1511-9.
[http://dx.doi.org/10.1002/pro.5560020916] [PMID: 8401235]
[28]
Saha S, Raghava GPS. AlgPred: Prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res 2006; 34: W202-9.
[http://dx.doi.org/10.1093/nar/gkl343] [PMID: 16844994]
[29]
Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: Allergenicity prediction by descriptor fingerprints. Bioinformatics 2014; 30(6): 846-51.
[http://dx.doi.org/10.1093/bioinformatics/btt619] [PMID: 24167156]
[30]
Yan Y, Tao H, He J, Huang SY. The HDOCK server for integrated protein–protein docking. Nat Protoc 2020; 15(5): 1829-52.
[http://dx.doi.org/10.1038/s41596-020-0312-x] [PMID: 32269383]
[31]
Gasteiger EHC, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. The Proteomics Protocols Handbook. Humana press 2005.
[32]
Hebditch M, Carballo-Amador MA, Charonis S, Curtis R, Warwicker J. Protein–Sol: A web tool for predicting protein solubility from sequence. Bioinformatics 2017; 33(19): 3098-100.
[http://dx.doi.org/10.1093/bioinformatics/btx345] [PMID: 28575391]
[33]
Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera?A visualization system for exploratory research and analysis. J Comput Chem 2004; 25(13): 1605-12.
[http://dx.doi.org/10.1002/jcc.20084] [PMID: 15264254]
[34]
Shannon P, Markiel A, Ozier O, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13(11): 2498-504.
[http://dx.doi.org/10.1101/gr.1239303] [PMID: 14597658]
[35]
Doncheva NT, Klein K, Domingues FS, Albrecht M. Analyzing and visualizing residue networks of protein structures. Trends Biochem Sci 2011; 36(4): 179-82.
[http://dx.doi.org/10.1016/j.tibs.2011.01.002] [PMID: 21345680]
[36]
Madeira F, Park Y, Lee J, et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res 2019; 47(W1): W636-41.
[http://dx.doi.org/10.1093/nar/gkz268] [PMID: 30976793]
[37]
Grote A, Hiller K, Scheer M, et al. JCat: A novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res 2005; 33: W526-31.
[http://dx.doi.org/10.1093/nar/gki376] [PMID: 15980527]
[38]
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581(7807): 215-20.
[http://dx.doi.org/10.1038/s41586-020-2180-5] [PMID: 32225176]
[39]
Kiyoshi M, Caaveiro JMM, Tada M, et al. Assessing the heterogeneity of the Fc-glycan of a therapeutic antibody using an engineered FcγReceptor IIIa-immobilized column. Sci Rep 2018; 8(1): 3955.
[http://dx.doi.org/10.1038/s41598-018-22199-8] [PMID: 29500371]
[40]
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020; 215: 108448.
[http://dx.doi.org/10.1016/j.clim.2020.108448] [PMID: 32353634]
[41]
Shamsi A, Mohammad T, Anwar S, et al. Potential drug targets of SARS-CoV-2: From genomics to therapeutics. Int J Biol Macromol 2021; 177: 1-9.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.02.071] [PMID: 33577820]
[42]
Adeniji OS, Giron LB, Purwar M, et al. COVID-19 severity is associated with differential antibody Fc-mediated Innate immune functions. MBio 2021; 12.
[43]
Chen X, Rostad CA, Anderson LJ, et al. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology 2021; 559: 1-9.
[http://dx.doi.org/10.1016/j.virol.2021.03.009] [PMID: 33774551]
[44]
Tso FY, Lidenge SJ, Poppe LK, et al. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. PLoS One 2021; 16(3): e0247640.
[http://dx.doi.org/10.1371/journal.pone.0247640] [PMID: 33661923]
[45]
Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021; 11(1): 316-29.
[http://dx.doi.org/10.7150/thno.49713] [PMID: 33391477]
[46]
Hu B, Huang S, Yin L. The cytokine storm and COVID‐19. J Med Virol 2021; 93(1): 250-6.
[http://dx.doi.org/10.1002/jmv.26232] [PMID: 32592501]
[47]
Ye Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment. J Infect 2020; 80: 607-13.
[http://dx.doi.org/10.1016/j.jinf.2020.03.037] [PMID: 32283152]
[48]
Lee P, Kim CU, Seo SH, Kim DJ. Current status of covid-19 vaccine development: Focusing on antigen design and clinical trials on later stages. Immune Netw 2021; 21(1): e4.
[http://dx.doi.org/10.4110/in.2021.21.e4] [PMID: 33728097]
[49]
Haraya K, Tachibana T, Igawa T. Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metab Pharmacokinet 2019; 34(1): 25-41.
[http://dx.doi.org/10.1016/j.dmpk.2018.10.003] [PMID: 30472066]
[50]
Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021; 892: 173751.
[http://dx.doi.org/10.1016/j.ejphar.2020.173751] [PMID: 33245898]
[51]
Puledran B, Ahmed R, Lee E, Querec T. Systems biology approach predicts immunogenicity of vaccines. US2011/0105343 A1, 2011.
[52]
Chan JFW, Yip CCY, To KKW, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol 2020; 58(5): e00310-20.
[http://dx.doi.org/10.1128/JCM.00310-20] [PMID: 32132196]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy